Literature DB >> 11522810

The relative effect of Alzheimer's disease and related dementias, disability, and comorbidities on cost of care for elderly persons.

D H Taylor1, M Schenkman, J Zhou, F A Sloan.   

Abstract

OBJECTIVES: Our primary objectives were (a) to determine the relative impact of Alzheimer's disease and related dementias (ADRD), disability, and common comorbid health conditions on the cost of caring for community-dwelling elderly person and (b) to determine whether ADRD serves as an effect modifier for the effect of disability and common comorbidities on costs.
METHODS: Participants were drawn from community respondents to the 1994 National Long Term Care Survey. The authors compared total cost of caring for persons without ADRD with that of those who had moderate and severe ADRD. Using regression analysis, the author identified the adjusted effect of ADRD, limitations in activities of daily living (ADLs), and common comorbidities on total costs.
RESULTS: Persons with severe ADRD had higher median total costs ($10,234) than did persons with moderate ADRD ($4,318) and those without ADRD ($2,268, p <.001). However, disability measured by ADL limitations was a more important predictor of total cost than was ADRD status in both stratified and multivariate analyses. Comorbidities such as heart attack, stroke, and chronic obstructive pulmonary disease also increased costs. Severe ADRD was an effect modifier for ADL limitations, increasing the positive impact of disability on total costs among persons with severe ADRD, but not for comorbidities. DISCUSSION: Disability, severe ADRD, and comorbidity all had independent effects that increased total costs. Thus, any risk adjustment procedure should account for disability and comorbidity and not just ADRD status.

Entities:  

Mesh:

Year:  2001        PMID: 11522810     DOI: 10.1093/geronb/56.5.s285

Source DB:  PubMed          Journal:  J Gerontol B Psychol Sci Soc Sci        ISSN: 1079-5014            Impact factor:   4.077


  23 in total

Review 1.  Alzheimer's disease: the strength of association of costs with different measures of disease severity.

Authors:  J Mauskopf; J Racketa; E Sherrill
Journal:  J Nutr Health Aging       Date:  2010-10       Impact factor: 4.075

Review 2.  The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease.

Authors:  Jaclyn Cappell; Nathan Herrmann; Stephen Cornish; Krista L Lanctôt
Journal:  CNS Drugs       Date:  2010-11       Impact factor: 5.749

3.  Disability in the oldest-old: incidence and risk factors in the 90+ study.

Authors:  Daniel J Berlau; Maria M Corrada; Carrie B Peltz; Claudia H Kawas
Journal:  Am J Geriatr Psychiatry       Date:  2012-02       Impact factor: 4.105

Review 4.  A systematic review to assess the policy-making relevance of dementia cost-of-illness studies in the US and Canada.

Authors:  Mark Oremus; S Carolina Aguilar
Journal:  Pharmacoeconomics       Date:  2011-02       Impact factor: 4.981

5.  Frailty in Relation to the Risk of Alzheimer's Disease, Dementia, and Death in Older Chinese Adults: A Seven-Year Prospective Study.

Authors:  C Wang; X Ji; X Wu; Z Tang; X Zhang; S Guan; H Liu; X Fang
Journal:  J Nutr Health Aging       Date:  2017       Impact factor: 4.075

6.  Galantamine: a pharmacoeconomic review of its use in Alzheimer's disease.

Authors:  Katherine A Lyseng-Williamson; Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

7.  Healthcare utilization and costs in primary care patients with dementia: baseline results of the DelpHi-trial.

Authors:  Bernhard Michalowsky; Steffen Flessa; Tilly Eichler; Johannes Hertel; Adina Dreier; Ina Zwingmann; Diana Wucherer; Henriette Rau; Jochen René Thyrian; Wolfgang Hoffmann
Journal:  Eur J Health Econ       Date:  2017-02-03

8.  The effects of patient function and dependence on costs of care in Alzheimer's disease.

Authors:  Carolyn W Zhu; Christopher Leibman; Trent McLaughlin; Nikolaos Scarmeas; Marilyn Albert; Jason Brandt; Deborah Blacker; Mary Sano; Yaakov Stern
Journal:  J Am Geriatr Soc       Date:  2008-07-24       Impact factor: 5.562

9.  Patient dependence and longitudinal changes in costs of care in Alzheimer's disease.

Authors:  Carolyn W Zhu; Christopher Leibman; Trent McLaughlin; Arthur S Zbrozek; Nikolaos Scarmeas; Marilyn Albert; Jason Brandt; Deborah Blacker; Mary Sano; Yaakov Stern
Journal:  Dement Geriatr Cogn Disord       Date:  2008-10-22       Impact factor: 2.959

10.  The ACTIVE cognitive training trial and predicted medical expenditures.

Authors:  Fredric D Wolinsky; Henry W Mahncke; Mark Kosinski; Frederick W Unverzagt; David M Smith; Richard N Jones; Anne Stoddard; Sharon L Tennstedt
Journal:  BMC Health Serv Res       Date:  2009-06-29       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.